Ultragenyx Pharmaceutical Q1 2024 GAAP EPS $(2.03) Misses $(1.77) Estimate, Sales $108.833M Miss $116.009M Estimate
Ultragenyx Pharmaceutical Q1 2024 GAAP EPS $(2.03) Misses $(1.77) Estimate, Sales $108.833M Miss $116.009M Estimate
Ultragenyx Pharmaceutical 2024年第一季度GAAP每股收益（2.03）未达到预期（1.77）美元，销售额为1.0833亿美元，未达到1.16009亿美元的预期
Ultragenyx Pharmaceutical (NASDAQ:RARE) reported quarterly losses of $(2.03) per share which missed the analyst consensus estimate of $(1.77) by 14.69 percent. The company reported quarterly sales of $108.833 million which missed the analyst consensus estimate of $116.009 million by 6.19 percent. This is a 8.30 percent increase over sales of $100.496 million the same period last year.
Ultragenyx Pharmaceutical（纳斯达克股票代码：RARE）公布的季度每股亏损为2.03美元，比分析师普遍预期的1.77美元（1.77美元）低14.69％。该公司公布的季度销售额为1.08833亿美元，比分析师普遍预期的1.16009亿美元低6.19％。这比去年同期的1.00496亿美元的销售额增长了8.30％。